Cargando…
Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics
Pancreatic cancer is one of the most lethal tumors, and reliable detection of early-stage pancreatic cancer and risk diseases for pancreatic cancer is essential to improve the prognosis. As 260 genes were previously reported to be upregulated in invasive ductal adenocarcinoma of pancreas (IDACP) cel...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007017/ https://www.ncbi.nlm.nih.gov/pubmed/27579675 http://dx.doi.org/10.1371/journal.pone.0161009 |
_version_ | 1782451155351109632 |
---|---|
author | Yoneyama, Toshihiro Ohtsuki, Sumio Honda, Kazufumi Kobayashi, Makoto Iwasaki, Motoki Uchida, Yasuo Okusaka, Takuji Nakamori, Shoji Shimahara, Masashi Ueno, Takaaki Tsuchida, Akihiko Sata, Naohiro Ioka, Tatsuya Yasunami, Yohichi Kosuge, Tomoo Kaneda, Takashi Kato, Takao Yagihara, Kazuhiro Fujita, Shigeyuki Huang, Wilber Yamada, Tesshi Tachikawa, Masanori Terasaki, Tetsuya |
author_facet | Yoneyama, Toshihiro Ohtsuki, Sumio Honda, Kazufumi Kobayashi, Makoto Iwasaki, Motoki Uchida, Yasuo Okusaka, Takuji Nakamori, Shoji Shimahara, Masashi Ueno, Takaaki Tsuchida, Akihiko Sata, Naohiro Ioka, Tatsuya Yasunami, Yohichi Kosuge, Tomoo Kaneda, Takashi Kato, Takao Yagihara, Kazuhiro Fujita, Shigeyuki Huang, Wilber Yamada, Tesshi Tachikawa, Masanori Terasaki, Tetsuya |
author_sort | Yoneyama, Toshihiro |
collection | PubMed |
description | Pancreatic cancer is one of the most lethal tumors, and reliable detection of early-stage pancreatic cancer and risk diseases for pancreatic cancer is essential to improve the prognosis. As 260 genes were previously reported to be upregulated in invasive ductal adenocarcinoma of pancreas (IDACP) cells, quantification of the corresponding proteins in plasma might be useful for IDACP diagnosis. Therefore, the purpose of the present study was to identify plasma biomarkers for early detection of IDACP by using two proteomics strategies: antibody-based proteomics and liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomics. Among the 260 genes, we focused on 130 encoded proteins with known function for which antibodies were available. Twenty-three proteins showed values of the area under the curve (AUC) of more than 0.8 in receiver operating characteristic (ROC) analysis of reverse-phase protein array (RPPA) data of IDACP patients compared with healthy controls, and these proteins were selected as biomarker candidates. We then used our high-throughput selected reaction monitoring or multiple reaction monitoring (SRM/MRM) methodology, together with an automated sample preparation system, micro LC and auto analysis system, to quantify these candidate proteins in plasma from healthy controls and IDACP patients on a large scale. The results revealed that insulin-like growth factor-binding protein (IGFBP)2 and IGFBP3 have the ability to discriminate IDACP patients at an early stage from healthy controls, and IGFBP2 appeared to be increased in risk diseases of pancreatic malignancy, such as intraductal papillary mucinous neoplasms (IPMNs). Furthermore, diagnosis of IDACP using the combination of carbohydrate antigen 19–9 (CA19-9), IGFBP2 and IGFBP3 is significantly more effective than CA19-9 alone. This suggests that IGFBP2 and IGFBP3 may serve as compensatory biomarkers for CA19-9. Early diagnosis with this marker combination may improve the prognosis of IDACP patients. |
format | Online Article Text |
id | pubmed-5007017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-50070172016-09-27 Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics Yoneyama, Toshihiro Ohtsuki, Sumio Honda, Kazufumi Kobayashi, Makoto Iwasaki, Motoki Uchida, Yasuo Okusaka, Takuji Nakamori, Shoji Shimahara, Masashi Ueno, Takaaki Tsuchida, Akihiko Sata, Naohiro Ioka, Tatsuya Yasunami, Yohichi Kosuge, Tomoo Kaneda, Takashi Kato, Takao Yagihara, Kazuhiro Fujita, Shigeyuki Huang, Wilber Yamada, Tesshi Tachikawa, Masanori Terasaki, Tetsuya PLoS One Research Article Pancreatic cancer is one of the most lethal tumors, and reliable detection of early-stage pancreatic cancer and risk diseases for pancreatic cancer is essential to improve the prognosis. As 260 genes were previously reported to be upregulated in invasive ductal adenocarcinoma of pancreas (IDACP) cells, quantification of the corresponding proteins in plasma might be useful for IDACP diagnosis. Therefore, the purpose of the present study was to identify plasma biomarkers for early detection of IDACP by using two proteomics strategies: antibody-based proteomics and liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomics. Among the 260 genes, we focused on 130 encoded proteins with known function for which antibodies were available. Twenty-three proteins showed values of the area under the curve (AUC) of more than 0.8 in receiver operating characteristic (ROC) analysis of reverse-phase protein array (RPPA) data of IDACP patients compared with healthy controls, and these proteins were selected as biomarker candidates. We then used our high-throughput selected reaction monitoring or multiple reaction monitoring (SRM/MRM) methodology, together with an automated sample preparation system, micro LC and auto analysis system, to quantify these candidate proteins in plasma from healthy controls and IDACP patients on a large scale. The results revealed that insulin-like growth factor-binding protein (IGFBP)2 and IGFBP3 have the ability to discriminate IDACP patients at an early stage from healthy controls, and IGFBP2 appeared to be increased in risk diseases of pancreatic malignancy, such as intraductal papillary mucinous neoplasms (IPMNs). Furthermore, diagnosis of IDACP using the combination of carbohydrate antigen 19–9 (CA19-9), IGFBP2 and IGFBP3 is significantly more effective than CA19-9 alone. This suggests that IGFBP2 and IGFBP3 may serve as compensatory biomarkers for CA19-9. Early diagnosis with this marker combination may improve the prognosis of IDACP patients. Public Library of Science 2016-08-31 /pmc/articles/PMC5007017/ /pubmed/27579675 http://dx.doi.org/10.1371/journal.pone.0161009 Text en © 2016 Yoneyama et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Yoneyama, Toshihiro Ohtsuki, Sumio Honda, Kazufumi Kobayashi, Makoto Iwasaki, Motoki Uchida, Yasuo Okusaka, Takuji Nakamori, Shoji Shimahara, Masashi Ueno, Takaaki Tsuchida, Akihiko Sata, Naohiro Ioka, Tatsuya Yasunami, Yohichi Kosuge, Tomoo Kaneda, Takashi Kato, Takao Yagihara, Kazuhiro Fujita, Shigeyuki Huang, Wilber Yamada, Tesshi Tachikawa, Masanori Terasaki, Tetsuya Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics |
title | Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics |
title_full | Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics |
title_fullStr | Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics |
title_full_unstemmed | Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics |
title_short | Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics |
title_sort | identification of igfbp2 and igfbp3 as compensatory biomarkers for ca19-9 in early-stage pancreatic cancer using a combination of antibody-based and lc-ms/ms-based proteomics |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007017/ https://www.ncbi.nlm.nih.gov/pubmed/27579675 http://dx.doi.org/10.1371/journal.pone.0161009 |
work_keys_str_mv | AT yoneyamatoshihiro identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT ohtsukisumio identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT hondakazufumi identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT kobayashimakoto identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT iwasakimotoki identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT uchidayasuo identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT okusakatakuji identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT nakamorishoji identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT shimaharamasashi identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT uenotakaaki identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT tsuchidaakihiko identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT satanaohiro identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT iokatatsuya identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT yasunamiyohichi identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT kosugetomoo identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT kanedatakashi identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT katotakao identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT yagiharakazuhiro identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT fujitashigeyuki identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT huangwilber identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT yamadatesshi identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT tachikawamasanori identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics AT terasakitetsuya identificationofigfbp2andigfbp3ascompensatorybiomarkersforca199inearlystagepancreaticcancerusingacombinationofantibodybasedandlcmsmsbasedproteomics |